Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past ...

Even when no artificial intelligence (AI) is watching, writers are rewriting themselves, flattening their voices, policing ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

AI use in Kurdistan is surging, aiding youth employment and trade, but experts warn of privacy risks and future self-teaching systems matching human capabilities.

"I only heard about it this morning," Park Hae-soo says. "They briefed me right before this interview. It still hasn't quite ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Gordon Scott has been an active investor and ...